Massachusetts Pharmacist Pleads Guilty to Diverting Controlled Substances in Federal Case

What Happened in the Federal Prescription Drug Diversion Case?

Federal prosecutors in the District of New Hampshire announced that Rima Gerges-Maalouf, a Massachusetts pharmacist, pleaded guilty to diverting controlled prescription drugs while working at a pharmacy in northern New Hampshire.

According to the plea agreement described by the U.S. Attorney’s Office, Gerges-Maalouf worked as a per diem pharmacist in August 2024. While on duty, prosecutors said she removed medication powder from capsules and took prescription pills that were intended for patients. Prosecutors also stated that she ingested some of the controlled substances while at work.

The government described the conduct as dangerous because patients depend on prescribed medications for treatment, dosage accuracy, and safety. When a medication is altered, emptied, replaced, or diverted, the patient may receive something different from what the prescriber ordered.

Why Federal Prosecutors Take Pharmacist Diversion Cases Seriously

Prescription drug diversion cases are serious because they involve controlled substances, patient safety, healthcare trust, and regulated medical supply chains. When the accused person is a licensed pharmacist, nurse, doctor, or other healthcare professional, prosecutors may argue that the conduct involved an abuse of professional trust.

In this case, the U.S. Attorney’s Office emphasized that the allegations involved a licensed pharmacist and prescription drugs intended for patients. The Drug Enforcement Administration and the FDA Office of Inspections and Investigations led the investigation.

Federal prescription drug diversion cases may involve several sentencing and custody issues, including:

• The type and quantity of controlled substances involved
• Whether patients were placed at risk
• Whether the conduct occurred in a healthcare setting
• Whether the defendant held a position of professional trust
• Whether substance-use treatment history exists
• Whether restitution, licensing, or employment consequences may follow
• Whether the defendant may qualify for BOP programming or treatment

Potential Federal Prison Exposure

The charge of diverting controlled substances carries a maximum prison term of 4 years, a maximum fine of $250,000, and a term of supervised release of up to 1 year.

A maximum penalty is not the same as the expected sentence. The final sentence will be determined by a federal district court judge after considering the U.S. Sentencing Guidelines, the facts of the offense, the plea agreement, the defendant’s history and characteristics, mitigation, and other statutory sentencing factors.

In healthcare and prescription drug cases, sentencing preparation can be especially important. The defense may need to address professional history, treatment history, lack of prior criminal record, acceptance of responsibility, patient-impact issues, restitution if any, mental health or addiction-related context, and post-offense rehabilitation.

Controlled Substance Diversion and BOP Planning

If a defendant receives a federal prison sentence, the case does not end at sentencing. The Bureau of Prisons will review the judgment, Presentence Investigation Report, offense conduct, medical history, substance-use history, custody classification, and programming needs.

For prescription drug diversion defendants, BOP planning may include:

• Reviewing the Presentence Investigation Report for BOP-impact language
• Preparing for BOP designation and custody classification
• Documenting medical and mental health history
• Reviewing substance-use history for treatment-program considerations
• Evaluating RDAP issues if there is a documented substance-use disorder
• Understanding First Step Act time credits and program participation
• Preparing for self-surrender if allowed
• Planning for halfway house and home confinement eligibility
• Preparing for supervised release after custody

Can RDAP Matter in a Prescription Drug Diversion Case?

RDAP, the Residential Drug Abuse Program, may be relevant in some federal cases involving prescription drug misuse, but eligibility depends on the facts. BOP will look at documented substance-use history, timing, diagnosis, sentence length, offense exclusions, and available records.

A defendant should not wait until arriving at federal prison to think about RDAP. If substance-use history exists, it should be documented accurately and appropriately before sentencing. Poor documentation, missing treatment records, or vague statements can make RDAP review more difficult later.

RDAP does not apply to every case, and admission or early-release benefit is not guaranteed. However, for eligible defendants, RDAP planning can be one of the most important parts of federal prison preparation.

Why Sentencing Preparation Matters Before BOP Custody

In federal cases, the Presentence Investigation Report often follows the defendant throughout the sentence. It may affect custody classification, facility placement, program recommendations, RDAP review, medical designation, and release planning.

That is why defendants and families should prepare early. What appears to be a small detail before sentencing can become a major issue once the Bureau of Prisons begins reviewing the file.

Prison Law Firm helps federal defendants, families, and lawyers understand how sentencing documents may affect the prison side of the case. This includes reviewing BOP designation issues, RDAP eligibility, First Step Act credits, home confinement timing, halfway house planning, sentence calculation, and supervised release preparation.

Source

This article is based on a public release from the U.S. Attorney’s Office for the District of New Hampshire titled “Massachusetts Pharmacist Pleads Guilty to Diverting Controlled Substances.”

Read the Department of Justice release.